MedTrace Logo

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

NCT04042753 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

Conditions

  • Pituitary
  • Pituitary Tumor
  • Pituitary Carcinoma
  • Pituitary Cancer

Interventions

DRUG

Ipilimumab

Ipilimumab 3 mg/kg every 3 weeks,

DRUG

Nivolumab

Nivolumab 1 mg/kg every 3 weeks for 4 cycles

DRUG

Nivolumab

Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first

Sponsors & Collaborators

Principal Investigators

  • Andrew Lin, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04042753 on ClinicalTrials.gov